Tests enavogliflozin to prevent atrial fibrillation returning after ablation
Tests enavogliflozin against placebo in adults with atrial fibrillation and heart failure after ablation.
Key facts
- Who runs it
- Yonsei University
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 390 people, planned
- Started
- 3 Apr 2025
- Expected to end
- 31 May 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Enavogliflozin
- Placebo
- Record updated
- 12 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with atrial fibrillation and heart failure who had a catheter ablation in the last three months or are about to have one. It tests Enavogliflozin against a placebo.
- Age
- 19 to under 85 years
- Sex
- Women and men can join.
- Disease stage
- Atrial fibrillation together with heart failure, with catheter ablation done within the last three months or planned.
- Earlier treatment
- Must not be treated with an SGLT-2 inhibitor now. Must not have used oral prednisolone at 10mg/day or equivalent, or higher steroid doses, within the last month.
Main reasons for not taking part
- Pregnant or breastfeeding women
- Currently on an SGLT-2 inhibitor
- Reduced kidney function (eGFR CKD-EPI < 60 ml/min/1.73m²)
- Type 1 diabetes or diabetic ketoacidosis
- Severe valvular disease or an artificial valve
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Adults aged 19 to under 85
- Patients who consent to participate in the study and can be followed up during the study
- Patients with AF and heart failure who have undergone atrial fibrillation catheter ablation within the last three months or are scheduled to undergo the procedure
Who cannot take part
- Currently being treated with an SGLT-2 inhibitor
- Continuous use of oral prednisolone at 10mg/day or equivalent, or higher doses of steroids, within the last month
- Three or more urinary or genital infections within the last year
- Uncontrolled hypertension: systolic blood pressure ≥ 180mmHg or diastolic blood pressure ≥ 110mmHg
- Severe valvular disease or presence of artificial valves
- Patients with active cancer (including those undergoing treatment) or history of cancer within the last five years at the time of screening; however, borderline cancers are not excluded if successfully treated and recurrence-free for 2-3 years
- Patients with hypersensitivity or history of hypersensitivity to the active or inactive ingredients of this drug
- Patients with type 1 diabetes or diabetic ketoacidosis
- History of alcohol or substance abuse
- Renal impairment (eGFR CKD-EPI < 60 ml/min/1.73m²)
- Under 19 or over 85 years old
- Patients who have participated in another clinical trial within the last three months
- Life expectancy of less than one year
- Pregnant or breastfeeding women
- Systolic blood pressure < 90mmHg
- Acute cardiovascular event within the last 12 weeks
- Clinically confirmed liver dysfunction
- Uncontrolled thyroid dysfunction
- Women of childbearing potential who do not agree to use adequate contraception during the clinical trial period
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 19 and 84 years old?
Where in South Korea
- Severance hospitalSeoul, South KoreaContact: Yong-ho Lee, Ph.D.Taking people
About the trial
What the trial wants to find out
Objective: The purpose of this study is to determine if there is a difference in the recurrence rate of atrial fibrillation (AF) between a group of patients with AF and heart failure undergoing catheter ablation who are administered the SGLT2 inhibitor, Enavogliflozin, and a control group (placebo group). This study aims to investigate whether SGLT2 inhibitors can prevent the recurrence of AF after the procedure.
Read full original descriptionShow less
Background: AF is the most common arrhythmia requiring treatment, with its prevalence increasing with age. In the US, AF affected 5.2 million people in 2010 and is projected to reach 12.1 million by 2030. In South Korea, prevalence rose from 0.73% in 2006 to 1.53% in 2015. Early-stage AF patients benefit more from rhythm control therapy than from heart rate control alone, as shown by the 2020 EAST-AFNET-4 trial, which reported a 21% reduction in adverse cardiovascular events. Catheter ablation for rhythm control significantly reduces AF recurrence compared to antiarrhythmic drugs, leading to more patients undergoing this procedure. AF and heart failure often coexist, forming a vicious cycle that exacerbates both conditions and leads to poorer outcomes. They share common risk factors like hypertension, diabetes, ischemic heart disease, and valvular disease. Heart failure increases left atrial filling pressure and alters intracellular calcium levels, raising AF risk. Further research is needed on their pathophysiological link. SGLT2 inhibitors reduce glucose reabsorption in the kidneys to control hyperglycemia in diabetics and have been shown in large studies (DAPA-HF, EMPEROR-Reduced) to significantly reduce heart failure worsening and cardiovascular mortality, regardless of diabetes status. These benefits were seen in both HFrEF and HFpEF. In the DAPA-HF trial, 55% of participants were non-diabetic, and reductions in heart failure worsening or cardiovascular death were similar between those with and without diabetes (25% vs. 27%). Adverse events, including volume depletion and renal function decline, were not significantly different between diabetic and non-diabetic patients, and no hypoglycemia or ketoacidosis occurred in non-diabetic patients. Recent studies show SGLT2 inhibitors reduce AF incidence and benefit heart failure. A sub-analysis of the DECLARE-TIMI 58 trial reported a 19% reduction in AF risk among diabetic patients with SGLT2 inhibitors. Meta-analyses by Okunrintemi and Zheng showed an 18% reduction in AF risk irrespective of diabetes status. Interest is growing in the relationship between SGLT2 inhibitors and AF recurrence post-catheter ablation. Luo et al. reported a nearly 39% reduction in AF recurrence post-ablation with dapagliflozin in diabetic patients. Kishima et al. found a 49% reduction in AF recurrence post-ablation with SGLT2 inhibitors versus DPP-IV inhibitors in a small prospective randomized study. However, most studies were retrospective, sub-analyses, or small-scale studies limited to diabetics. Prospective randomized studies involving AF patients regardless of diabetes status are urgently needed for validation.
The 2 groups in the trial
- EnavogliflozinTreatment being tested
Enavogliflozin as a study group
- PlaceboPlacebo, for comparison
Placebo as a comparison group
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- ENavogliflozin And preVention Of Atrial Fibrillation Recurrence After Catheter Ablation for Atrial Fibrillation With Heart Failure (ENAVO-AF): Prospective, Multicenter, Randomized, Placebo-controlled Double-blind Clinical Trial
- Plain-language title
- Tests enavogliflozin to prevent atrial fibrillation returning after ablationGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06528262, who can take part
- Record updated
- 12 May 2026